Endocrinopathies in survivors of childhood neoplasia

Nicole Barnes¹ and Wassim Chemaitilly¹,² *

¹ Division of Pediatric Endocrinology, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USA
² Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN, USA

INTRODUCTION

Approximately 1 in 285 children will be diagnosed with cancer before the age 20 years, and 1 in 530 young adults between the ages of 20 and 39 years is a childhood cancer survivor (CCS) (1). Endocrine complications are among the most common sequelae observed in CCS, and they frequently occur as cancer therapy-related late – effects appearing years, even decades, after the exposure to chemotherapy and/or radiotherapy. The prevalence of an endocrine disorder in 1423 adult CCS was reported to be 62% (95% CI 59.5–64.6) (2). The 60-year cumulative risk of having an endocrinopathy in an individual diagnosed with cancer between the ages of 5 and 9 years was 43% in a large cohort of Northern European CCS (3). The occurrence of endocrine disorders documented in an Italian Transition Unit for adult CCS was 48.46 and 62.78% in females and males, respectively (Figure 1) (4). Treatment exposures placing individuals at risk of endocrinopathies have traditionally included alkylating agent based chemotherapy and radiotherapy. More recently, selective mitogen-activated kinase inhibitors and immune system modulators have been shown to also be associated with endocrine dysfunction. The long-term consequences of the use of these novel therapies, some of which are prescribed in maintenance regimens, remain to be fully elucidated (5–7). Healthcare providers should be equipped to diagnose and manage acute and long-term endocrine complications that may arise in maturing CCS. This review will address the risk of endocrine disorders associated with the treatment of pediatric cancer and brain tumors. The data summarized in this review are based on a systematic search of the medical literature using MEDLINE/Pubmed (from 1970 to May 2014) using keywords relevant to this topic. Additional searches were conducted within the reference lists of relevant articles.

DISORDERS OF THE HYPOTHALAMUS AND PITUITARY

Tumor development and/or surgical resections close to the hypothalamus and/or pituitary may induce direct anatomical damage to these structures and result in multiple hypothalamic/pituitary dysfunctions (Table 1). Disorders of the hypothalamus/pituitary are also common following their exposure to direct or scatter radiotherapy. More recently, Iplimumab, an immune system modulator, was shown to potentially cause auto-immune hypophysitis with ensuing anterior panhypopituitarism (7). Pituitary dysfunction was the most frequent endocrine complication in a Northern European cohort comparing 31,723 CCS and 211,261 controls. In this study, the standard hospitalization rate ratio of hypopituitarism was 88.0 (95% CI 72.1–107.5) in CCS when compared to matched controls from the local general population (3).

GROWTH HORMONE DEFICIENCY AND POOR LINEAR GROWTH

Growth failure and short stature are among the most common sequelae of childhood cancer therapy (8). Several etiologies may contribute to growth failure in CCS including growth hormone deficiency (GHD), exposures to spinal and total-body irradiation (TBI), pubertal disorders, chemotherapy treatments including glucocorticoids, hypothryoidism, suboptimal nutrition, and renal disease (9–12).

In CCS, GHD is frequently attributed to cranial radiotherapy doses of 12–64 Gy to the hypothalamus/pituitary (4). Radiation has a dose and time dependent effect on GH secretion. Merchant et al. demonstrated that GHD was likely to develop within 36 months of exposure to hypothalamic/pituitary radiotherapy in individuals receiving doses ≥20 Gy (13) (Figure 2). In comparison to radiotherapy, the impact of chemotherapy alone on GHD secretion is more controversial and less common (14–17). Imatinib, a tyrosine kinase inhibitor (TKI), has been associated with
growth deceleration and with failure of provocative GH stimulation testing (18, 19). Imatinib is presumed to inhibit bone growth by impeding the kinase mediated release of GH (5).

Growth hormone deficiency should be investigated in skeletally immature CCS when linear growth velocity decelerates over a 6-month period. The effect of GHD on growth may be masked by precocious puberty and by hyperinsulinemia in the context of rapid weight gain (“growth without growth hormone”) with seemingly normal linear growth driven by sex steroids and insulin respectively in affected individuals (20, 21). CCS exposed to spinal radiotherapy are at risk of having skeletal disproportions; this should ideally be investigated by measuring the sitting height (12). Biochemical evaluation for GHD requires dynamic testing, which despite limitations related to poor reproducibility in the general population, remains acceptable for the assessment of GH secretion in CCS (22). In the general population, the diagnosis of GHD typically requires failing dynamic tests using two different secretagogues; however, in CCS exposed to cranial radiotherapy and individuals with a history of a brain tumor close to the hypothalamus/pituitary, failing one test was considered sufficient in the consensus guidelines published by the Growth Hormone Research Society (23). Secretagogues used in dynamic testing include insulin, arginine, levodopa, clonidine, and glucagon. GH releasing hormone (GHRH) should not be used for the assessment of GH secretion in this population given the primarily hypothalamic location of radiation-induced damage (24). Plasma levels of IGF-1 and IGFBP3, although commonly practiced, are not reliable screening tools in CCS exposed to cranial radiotherapy and are associated with high rates of false-negatives (25).

Treatment with recombinant GH (rGH) replacement therapy is typically not initiated until 12 months after successfully completing cancer or brain tumor treatments. The mitogenic potential of GH stimulating tumor growth is a safety concern in CCS (26). Studies suggest that rGH in patients with brain tumors are not associated with primary disease recurrence (27–29). However, there may be an increase in the development of second neoplasm in CCS treated with GH (30, 31). Ergun-Longmire et al. reported a relative risk of 2.15 (95% CI, 1.3–3.5; \( p < 0.002 \)) of developing a second neoplasm in CCS treated with rGH when compared to controls and the most commonly identified neoplasms were meningiomas (30). Nevertheless, using the same multi-center cohort of CCS and reporting specifically on the risk of subsequent central nervous system neoplasms after a longer period of follow-up, Patterson et al. recently reported an adjusted rate ratio of meningioma and gliomas in GH treated survivors of CNS tumors when compared to CNS tumor survivors who were not treated with GH of 1.0 (95% CI 0.6–1.8, \( p = 0.94 \)), thus indicating negligible differences between the two groups in regards to this particular risk (32).

The benefits of rGH extend beyond linear growth and are highlighted in adult GHD studies. Some of the advantages include improvements in bone mineral density (BMD), cardiovascular function, reduction in metabolic syndrome, and sustained improvements in quality of life (33). The benefits and risk of rGH have to be carefully weighed in children and adult survivors. Ongoing studies are needed to investigate and characterize the risk of developing second neoplasms as well as the proposed advancements in the physiological and psycho-social well-being of rGH in CCS.

**DISORDERS OF LUTEINIZING HORMONE AND FOLLICLE-STIMULATING HORMONE**

**Central precocious puberty**

Central precocious puberty (CPP) is defined by the early activation of the hypothalamic–pituitary–gonadal axis leading to the onset of puberty prior to the ages of 8 and 9-years in girls and boys, respectively (34, 35). The consequences of CPP include the premature closure of growth plates resulting in decreased adult height prospects. Precocious puberty, especially menarche, can generate
Table 1 | Central endocrinopathies.

| Function | Complication | Therapy-related risks | Relationship to time, dose to gland, or organ when applicable | Evaluation/labs | Intervention |
|----------|--------------|-----------------------|---------------------------------------------------------------|-----------------|--------------|
| Linear growth | GH deficiency | Surgery | Damage to the pituitary by tumor expansion and/or surgery
Doses ≥18 Gy (highest risk ≥30 Gy) | Bone age
IGF1, IGF-BP3
GH stimulation test | GH replacement |
| Linear growth | Radiotherapy to hypothalamus/pituitary | | | | |
| Puberty | Central precocious puberty | Radiotherapy to hypothalamus/pituitary | Doses ≥18 Gy, Girls <5 years old at exposure have a higher risk | Bone age
Baseline AM LH, FSH, estradiol (girls), or testosterone (boys)
Leuprolide stimulation test | GnRH agonist |
| Puberty | LH/FSH deficiency* | Surgery | Damage to the pituitary by tumor expansion or growth
Doses ≥30 Gy
Partial deficit ≥20 Gy | Bone age
Baseline AM LH, FSH, estradiol (girls), or testosterone (boys) | Induction of puberty/sex hormone replacement therapy |
| Puberty | Radiotherapy to hypothalamus/pituitary | | | | |
| Pituitary | ACTH insufficiency* | Surgery | Damage to the pituitary by tumor expansion and/or surgery
Doses ≥30 Gy
Deficiency depends on the doses used and duration of exposure | 8 a.m. cortisol and ACTH | Hydrocortisone and stress dose teaching |
| Pituitary | Radiation to hypothalamus or pituitary
Systemic glucocorticoids | | | | |
| Pituitary | Irradiation to hypothalamus/pituitary | | | | |
| Pituitary | TSH deficiency* | Surgery | Damage to the pituitary by tumor expansion and/or surgery
Doses ≥30 Gy | Free T4 | Levothyroxine |
| Pituitary | Radiotherapy to hypothalamus/pituitary | | | | |
| Central diabetes insipidus | Surgery | Damage to the pituitary by tumor expansion and/or surgery | Plasma electrolytes, serum, and urinary osmolalities.
Water deprivation test in equivocal situations | Desmopressin
Fluid management | |

GH, growth hormone; IGF-1, insulin-like growth factor-1; IGF-BP3, insulin-like growth factor binding protein 3; GnRH, gonadotropin releasing hormone; ACTH, corticotropin; TSH, thyroid stimulating hormone; AM, morning sample; LH, luteinizing hormone; FSH, follicle-stimulating hormone.

*Also described in the context of ipilimumab-induced anterior hypophysitis.

significant psycho-social adjustment challenges in young children, particularly in those with special needs. While radiotherapy to the hypothalamus/pituitary is the main risk factor associated with CPP in CCS; pubertal development can also be triggered prematurely by tumors located near the hypothalamus or optic pathways independently from radiation exposure. Additional risk factors include hydrocephalus, female sex, exposure to radiotherapy before the age of 5 years, and increased BMI (36, 37).

The mean linear velocity in children with CPP can be 8–10 cm/year (+2 to +4 SDS for chronological age) at diagnosis (38); however, in CCS the linear growth velocity may be normal or poor secondary to concurrent GHD or spinal damage from radiotherapy (39). Clinicians should not rely on the measurement of testicular volume for the diagnosis of puberty in males exposed to gonadotoxic chemotherapy regimens (as those with alkylating agents) and/or testicular irradiation. In these individuals, treatment-related germ cell injury can impair testicular growth without necessarily affecting their ability to produce testosterone and this can be particularly misleading in the context of CPP. Clinicians should be aware of these caveats and have a low threshold to initiate laboratory testing if there is suspicion of early pubertal growth based on other clinical markers such as penile enlargement, scrotal skin thinning, or pubarche.

Biochemical evidence of CPP includes pubertal basal levels of luteinizing hormone (LH) and sex steroids (estradiol or testosterone). Random basal values may be inconclusive secondary to the pulsatile nature of gonadotropins and stimulated values may be necessary to establish the diagnosis. GnRH agonists are used in stimulation testing and a pubertal LH value and a LH to follicle-stimulating hormone (FSH) ratio >1 is consistent with CPP (34, 40). Radiographic evaluation encompasses an assessment of a child’s skeletal maturation (41, 40). In females a pelvic ultrasound demonstrating pubertal sized uterus and ovaries may also be helpful in confirming the diagnosis (42).

Treatment with a GnRH agonist suppresses the secretion of gonadotropins and may be useful in improving final height
insufficiency, can occur in CCS following tumor and/or surgery-related damage or after the exposure of the hypothalamus/pituitary to radiotherapy doses ≥30 Gy (49). Hudson et al. identified disorders of the hypothalamic–pituitary–adrenal axis in 13.8% of CCS exposed to cranial radiotherapy (2). In a study of children with embryonal brain tumors treated with radiotherapy, the 4-year cumulative incidence of ACTH deficiency was 38 ± 6% and there was no significant difference in those patients who received irradiation of >42 and <42 Gy (50). The incidence of ACTH deficiency in patients receiving TBI as part of preconditioning of BMT has been reported at 6% (51) ACTH deficiency was documented in 60% (n = 50) of patients receiving BMT for malignant and non-malignant reasons. It was more likely to occur in patients who had been transplanted <1 year prior to testing and all the subjects who were diagnosed were asymptomatic (15). The clustering of ACTH deficiency cases within a year of transplant in this study suggests that a large proportion of patients experience transient forms of this condition as a result of their exposure to high-dose glucocorticoids. More recently, ACTH deficiency has been associated with the use of imatinib, a TKI with 48% of individuals diagnosed 3–71 months following the exposure (52). Ipilimumab, an immune system modulator can cause auto-immune hypophysitis with ensuing panhypopituitarism, especially at doses >3 mg/kg with a reported prevalence of 4.9–17% (7, 53, 54). The onset of hypophysitis may not occur until 6 weeks after therapy and affected individuals may require 2–5 years of glucocorticoid therapy (55). Future investigations are needed to determine when and for how long CCS treated with these agents should be tested. If patients are deemed insufficient, the chronicity of the insufficiency should also be studied.

Symptoms of ACTH deficiency include fatigue, weakness, nausea, vomiting, anorexia, and abdominal cramping. When exposed to a severe illness, patients with ACTH deficiency may develop life-threatening complications including hypoglycemia related seizures and hypotensive shock. Untreated ACTH deficiency may be associated with decreased free water clearance and hyponatremia; replacement with hydrocortisone in such instances, especially in post-surgical patients, may unmask co-existent central diabetes insipidus. A screening cortisol level, collected at 8 a.m. that is ≥10 mcg/dl is reassuring and against the presence of ACTH deficiency; a value ≤5 mcg/dl at 8 a.m. should in contrast raise high suspicions regarding this diagnosis. Definitive testing includes insulin tolerance, low dose cosyntropin or metyrapone stimulation tests. A peak cortisol value <18 µg/dl following low dose (1 microgram) cosyntropin is the most commonly used diagnostic criterion (56). The treatment of ACTH deficiency relies on replacement therapy with hydrocortisone and patient and family education regarding stress dosing during times of illness.

TSH DEFICIENCY

Thyroid stimulating hormone deficiency, also known as central hypothyroidism, is rarely reported in CCS. It can occur as a result of tumor and/or surgery related damage or after hypothalamic/pituitary exposure to radiotherapy doses ≥30 Gy (44, 50, 57, 58). One CCS study detected TSH deficiency in 6% (n = 71) of childhood brain tumor survivors (59). Deficiency in TSH may also occur in the context of ipilimumab-induced auto-immune hypophysitis, as detailed in Section “Corticotropin Deficiency” (7).

CORTICOTROPIN DEFICIENCY

Corticotropin (ACTH) deficiency, also known as central adrenal insufficiency, can occur in CCS following tumor and/or surgery.

FIGURE 2 | Growth hormone secretion after hypothalamic/pituitary exposures to radiotherapy. Reproduced with permission from Ref. (13) ©2011 by American Society of Clinical Oncology.
Hypothyroidism is associated with poor linear growth, delayed bone age, and disturbances in pubertal timing during childhood. It can also cause fatigue, fluid retention, constipation, cold intolerance, proximal muscle weakness, and depression. A serum free T4 (FT4) below normal in conjunction with a low or normal serum TSH is characteristic of TSH deficiency. Levothyroxine is used to treat this form of hypothyroidism with doses are adjusted to maintain FT4 values within mid to high normal ranges (60). In contrast to primary hypothyroidism (PH), serum TSH values are not helpful in the monitoring of this condition, as they are expected to remain low even after inadequate replacement with levothyroxine.

HYPERPROLACTINEMIA
Prolactin production by the pituitary gland is controlled by the hypothalamus, with a predominantly inhibitory tone due to dopaminergic input. Disruptions of hypothalamic–pituitary connections due to tumor growth, surgery, or doses of radiotherapy >30–50 Gy can result in hyperprolactinemia because of the loss of hypothalamic inhibition on prolactin secretion (44, 61, 62). Patients with hyperprolactinemia can present with galactorrhea. Furthermore, elevated prolactin levels may suppress LH and FSH production and cause hypogonadism. Nevertheless, hyperprolactinemia in CCS tends to remain asymptomatic, especially in a patient population where individuals are concurrently at risk of gonadotropin deficiency and primary gonadal failure because of their cancer treatment exposures (62).

CENTRAL DIABETES INSIPIDUS
Central diabetes insipidus is the clinical manifestation of the deficit in secretion and release of the anti-diuretic hormone (ADH). Hypothalamic neurons are responsible of the production of ADH; the latter is carried by axonal transport to the posterior pituitary from which it is released into the circulation. The deficiency in ADH impairs the affected individual’s ability to concentrate urine with ensuing polyuria, polydipsia, and dehydration when access to free water is compromised. Central diabetes insipidus can be a mode of revelation of childhood brain malignancies such as dysgerminomas or hypophyseal non-Hodgkin’s lymphomas (63, 64). In these instances, it can initially be isolated and as the tumoral infiltration worsens additional pituitary functions become deficient (64). More commonly, however, diabetes insipidus occurs in the context of pan-hypopituitarism due to the presence of a tumor in close proximity to the sellar region or as a consequence of surgical procedures aimed at removing it. Central diabetes insipidus does not occur as a late effect of cranial radiotherapy and is hence rarely discussed in the literature dedicated to CCS (65). Central diabetes insipidus does not seem to be associated with the use of ipilimumab (7). The management of central diabetes insipidus consists of replacement therapy using desmopressin with close monitoring of fluid intake and urine output in order to avoid overtreatment and ensuing hyponatremia and seizures. Significant shifts in replacement needs are noted in the post-operative patient, mandating close monitoring in the inpatient setting until stabilization is achieved (66, 67). This was well characterized following neurosurgical interventions on sellar/supra sellar tumors such as craniopharyngioma with the classical description of a triple phase response consisting of a first phase of transient diabetes insipidus lasting for up to 2 days, followed by an anti-diuretic phase of 1–2 weeks before the onset of permanent diabetes insipidus (67). Patients with altered thirst sensation are more easily managed with the determination of a fixed daily fluid requirement in addition to a fixed dose of desmopressin in order to avoid significant fluctuations in their hydration status (66).

DISORDERS OF THE THYROID
The radiosensitive nature of the thyroid gland predisposes it to dysfunctions including hypothyroidism, hyperthyroidism, nodules, and cancer (Table 2). Hudson et al. identified thyroid disorders in up to 66.4% of CCS exposed to neck radiotherapy (2). Thyroid dysfunction has been attributed to multiple cancer therapies including radiotherapy with direct or scatter exposure of the neck, TKI, 131 I-Metaibenzylguanidine ([131I] MIBG), retinoid X receptor agonist autoantibodies, angiogenesis inhibitor thalidomide, and interferon-α (68–70).

PRIMARY HYPOTHYROIDISM
Primary hypothyroidism is the most common thyroid abnormality in CCS. In a study by Armstrong et al., the relative risk of PH in CCS was 17.1 when compared to sibling controls (70). The study also documented that up to 50% Hodgkin lymphoma patients receiving >45 Gy developed hypothyroidism within 5 years (70). Female sex and older age at diagnosis were also associated with an increased incidence of hypothyroidism. The risk of PH has primarily been attributed to direct or scatter radiation of the neck including cranio-spinal radiotherapy as well as TBI for cytodestruction before HSCT (50, 58, 59, 71). Subclinical or compensated PH is more commonly diagnosed than overt PH in the context of low dose radiotherapy and HSCT, with some patients experiencing spontaneous recovery (58). Chemotherapy alone has not been traditionally associated with PH. However, TKIs such as sorafenib, sunitinib, and imatinib have been noted to cause thyroid dysfunction (72–74). Hypothyroidism during treatment with sunitinib occurred in 7–85% of patients (72, 73). The pathophysiology of TKI causing PH remains elusive; it may be secondary to destruction of the thyroid gland, impairments of thyroid hormone transport or metabolism, or reduced TSH clearance (72). PH was documented in 13 out 16 CCS of neuroblastoma treated with [131I] MIBG in a long-term follow-up study over a period of 15.5 years (11.2–20.2) (69).

Extended surveillance for thyroid dysfunction is crucial as hypothyroidism in CCS exposed to radiotherapy and radio-labeled agents may occur decades later. The clinical presentation of PH is similar to central hypothyroidism in CCS; however, biochemically they differ. The labs in PH include an elevated plasma TSH level with normal or low free T4; both values are used in monitoring replacement using levothyroxine at substitutive doses.

HYPERTHYROIDISM
Hyperthyroidism was diagnosed in up to 5% of survivors in a report by Armstrong et al., a rate that was 8 times greater than in sibling controls (70). Overt hyperthyroidism albeit rare has been reported in CCS after hematopoietic stem-cell transplant (HSCT) (75–77). The occurrence of hyperthyroidism may be
Table 2 | Peripheral endocrinopathies.

| Function | Complication | Therapy-related risks | Relationship to time, dose to gland, or organ when applicable | Evaluation/labs | Intervention |
|----------|--------------|-----------------------|---------------------------------------------------------------|----------------|-------------|
| Thyroid  | Primary hypothyroidism | Neck irradiation | Risk increases with dose and time after exposure | TSH, FT4 | Levothyroxine |
|          |              | I131 labeled agents | MIIG for neuroblastoma |                  |             |
|          | Hyperthyroidism | Neck irradiation | Doses ≥35 Gy | TSH, FT4, T3 | Dependent on clinical course |
|          | Auto-immune hypothyroidism | HSCT | Transfer of auto-immunity from donor | TSH, FT4 | Levothyroxine |
|          | Thyroid neoplasms | Neck irradiation | Doses 20–29 Gy < 10 at exposure | Yearly palpation of neck | Per etiology |
|          |              |                      | Females at higher risk | Thyroid US |             |
|          |              |                      |                  | US guided FNAB |             |
| Gonadal disorders | Leydig cell dysfunction | Testicular irradiation | Doses ≥24 Gy | AM LH, FSH, testosterone | Replacement therapy with testosterone |
| male     |              | Alkylating agents | Generally subclinical |                  |             |
|          | Germ cell dysfunction | Testicular irradiation | Possible ≥0.15 Gy | Baseline LH, FSH, inhibin B | Sperm banking |
|          |              | Alkylating agents | High risk ≥2 Gy | Adults: semen analysis | |
|          |              |                      | Cyclophosphamide dose ≥7.5 gram/m²a |                  |             |
|          |              |                      | MOPP ≥3 cycles |                  |             |
|          |              |                      | Busulfan ≥800 mg/m²a |                  |             |
|          |              |                      | Ifosfamide ≥60 g/m²a |                  |             |
|          |              |                      | Any alkylating agent in combination with radiotherapy to the testes | | |
| Gonadal disorders | Ovarian failure | Abdominopelvic irradiation | Acute ovarian failure doses ≥20 Gy | Baseline LH, FSH, estradiol | Induction of puberty with estradiol |
| female   |              |                          | Premature menopause/infertility at lower doses | Hormone replacement therapy | |
|          |              |                      | Higher risk at older age | Pubertal females-AMH | |
|          |              | Alkylating agents | Higher risk at older age |                  |             |
| Bone health | Osteoporosis | Radiotherapy | TBI Associated hormone deficiencies | BMD studies | Per etiology |
|          |              | Glucocorticoids, methotrexate | Nutritional/lifestyle causes | 25 Hydroxy-Vitamin D levels | |
| Metabolic | Obesity overweight | Surgery | Hypothalamic injury/central obesity | Waist to Hip Ratio | Lifestyle modifications – diet, physical activity | |
|          | Insulin resistance | Radiotherapy | Cranial radiotherapy abdominal radiation TBI | Fasting: glucose, lipids, insulin, HbA1c | Per etiology |
|          | Metabolic syndrome | Diabetes mellitus | | Oral glucose tolerance if fasting test abnormal | |

TBI: total-body irradiation; TSH: thyroid stimulating hormone; AM: morning sample; LH: luteinizing hormone; FSH: follicle-stimulating hormone; FNAB: ultrasound guided fine needle aspiration biopsy; TKI: tyrosine kinase inhibitors; AMH: anti-Mullerian hormone; BMD: bone mineral density.

Cumulative dose; source: long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers – Version 3.0-October 2008. Children’s Oncology Group – www.survivorshipguidelines.org.

more common shortly after HSCT with Jung et al. reporting a prevalence of 4.5% in the first 3 months following transplant (77). Lower prevalence values (0.7–2%) have been reported in studies incorporating long-term follow in the pediatric HSCT population (75, 76).

### AUTOIMMUNE INDUCED THYROID DISEASE

Positive thyroid autoantibodies have been reported in cases of hypothyroidism and hyperthyroidism in CCS of allogeneic HSCT (78, 79). It has been presumed to be related to the transfer of auto-immunity from the stem-cell donor to the HSCT recipient.
However, the presence of thyroid antibodies does not necessarily lead to progression to hypothyroidism in the context of HSCT (80). Autoimmune thyroiditis may exacerbate the thyroid toxicity of certain, but not all, TKI (72, 81). Autoimmune and non-autoimmune thyroiditis are also well established toxicities of interferon-α, a human recombinant cytokine used in the treatment of some solid tumors and hematologic malignancies (82). Newer anticancer agents such as the monoclonal antibodies have also been associated with rare cases of auto-immune hypothyroidism and transient hyperthyroidism. The incidences of ipilimumab-induced auto-immune hypothyroidism in small case reports have been 0–2, 7, and 19% in patients receiving standard doses, high doses, and combination therapy with bevacizumab, respectively (82).

THYROID NEOPLASMS

Second thyroid neoplasms may occur later than two decades after the diagnosis of the primary cancer in CCS (83, 84). Armstrong et al. conveyed that 20 years after diagnosis, the risk of having a thyroid nodule in CCS after exposure to neck irradiation was 20%, which is 27 times higher than the sibling population (70). The association between the development of thyroid cancer and direct or scatter radiation of the neck is well known (85). In a large cohort of 12,575 CCS, 111 cases of second primary cancers were pathologically confirmed in patients who had received radiotherapy (86). The most common second primary cancer was papillary thyroid carcinoma and the risk was highest in patients who had received ≤20 Gy, were of female and of a young age (<10 years) at the time of diagnosis of the primary cancer (86). Hodgkin lymphoma is the primary cancer most commonly associated with thyroid cancer. The cumulative incidence of thyroid cancer was 2.3% (95% CI, 1.7–3.1) in this population (83). A recent report by Veiga et al. suggested that alkylating agents in conjunction with <20 Gy of irradiation can increase the incidence of thyroid neoplasms by 2.4 (95% CI, 1.3–4.5; p = 0.002) (83).

The currently recommended screening modality for thyroid cancer in CCS at risk is the yearly clinical examination of the neck by an experienced provider. There is significant disagreement regarding the use of thyroid ultrasound for the purposes of screening in the absence of clinical symptoms, because of the high probability of finding abnormal results leading to higher rates of diagnostic procedures and unnecessary anxiety to patients and their families; the yield in identifying malignant nodules with ultrasonography is indeed low, even in survivors of Hodgkin lymphoma (87–90). Kovalchik et al. recently validated an absolute risk prediction model (AUC 0.80, 95% CI), screening for thyroid cancer in CCS. The model was based on sex, age ≤15 years at primary cancer diagnosis, history of thyroid nodule, radiotherapy to the neck, and exposure to alkylating agents (91). The diagnosis of second primary thyroid cancer in CCS relies on the presence of a positive result on a fine needle aspiration biopsy of a suspected nodule; the treatment approach and prognosis are identical to thyroid cancer cases diagnosed in the general population (87).

DISORDERS OF THE GONADS

MALES

The tests have two functional compartments, a reproductive compartment and an endocrine compartment (Table 2). The reproductive compartment consists of germ cells and the Sertoli cells that support them. The endocrine compartment encompasses the Leydig cells, which are responsible for producing testosterone. The two compartments are affected differently by cancer therapies and understanding this dichotomy in testicular function is imperative in counseling male CCS in regards to their risk of gonadal dysfunction.

Leydig cell dysfunction

Hypogonadism after chemotherapy exposure alone is rare (92, 93). However, high doses of alkylating agents, such as cyclophosphamide can cause low testosterone (94, 95). There are also case reports of broad acting kinase inhibitors causing low testosterone and gynecomastia (96). Leydig cell dysfunction as a result of testicular irradiation is dependent on the age of the exposure and the dose of irradiation. Pre-pubertal males receiving doses >24 Gy are at high risk for hypogonadism, whereas pubertal males are at risk when exposed to >33 Gy (97–99). An elevated LH and a low normal morning testosterone define subclinical hypogonadism, and can be attributed to moderate doses of alkylating agent and low dose of testicular irradiation (<20 Gy); however, subclinical hypogonadism rarely requires exogenous testosterone replacement therapy (99–101). At risk, CCS should be followed closely for signs and biochemical evidence of hypogonadism that warrant replacement therapy during pubertal years and adulthood.

Germ cell dysfunction

Germ cells are more sensitive to testicular irradiation and chemotherapy than Leydig cells. Chemotherapy agents associated with germ cell dysfunction include cyclophosphamide, procarbazine, ifosfamide, busulfan, melphalan, and cisplatin (99, 102). Green et al. reported germ cell dysfunction with subsequent azospermia in 38.2% (n = 275) males exposed to chemotherapy and/or testicular irradiation (103). Small testicular volume, elevated FSH, and low inhibin B levels are associated with poor fertility prognosis in males; however, these clinical and biochemical findings lack sensitivity and specificity in male CCS. Males exposed to gonadotoxic agents may recover germ cell function and it is recommended that they have semen analyses in order to determine fertility status (103, 104).

Sperm cryopreservation is recommended in cancer patients prior to therapy with gonadotoxic agents. In pre-pubertal males, an approach combining testicular tissue extraction, spermatogonial stem-cell preservation, and later transplantation of decontaminated (non-malignant) cells has been proposed but remains experimental (99, 105, 106).

FEMALES

The ovaries do not replicate the functional dichotomy (distinct endocrine and reproductive compartments) observed in the testes. The female ovarian follicle is responsible for estrogen production and oocyte maturation, and both functions are simultaneously...
affected by gonadal failure. The extent of ovarian damage and subsequent residual function do not solely depend on the intensity of the cancer treatments received by the patient. These also depend on the number of viable follicles, or “ovarian reserve,” at the time of the exposure. Patients whose viable follicles were depleted during therapy do not experience a recovery of their ovarian function after the completion of cancer treatments and are diagnosed with acute ovarian insufficiency (107). A subset of individuals, with a less severe but nevertheless significant depletion of their ovarian reserve, will experience a resumption of pubertal development or menstrual cycles in the few years following the completion of cancer therapy only to be diagnosed several years later with premature menopause, which is defined as ovarian failure prior to the age of 40 years (108). Given naturally declining numbers of follicles during a woman’s lifespan, ovarian reserve and, consequently, vulnerability to damage from gonadotoxic agents, are particularly dependent on chronological age at the time of exposure to cancer treatments (107, 108). Cancer treatments associated with ovarian toxicity include abdominopelvic irradiation (API) and chemotherapy agents such as cyclophosphamide, procarbazine, busulfan, melphalan, and thiotepa (107–110). Chemotherapy is less toxic to the ovaries of pre-pubertal females in comparison to pubertal and adult females (107, 111–113). The ovarian toxicity of API is age and dose dependent, irradiation doses >20 Gy in female, CCS >13 years old, and TBI in CCS >10-years is correlated with ovarian insufficiency (107, 114, 115). A study of an AML cohort treated with chemotherapy alone (anthracyclines and cytarabine) demonstrated that menarche occurred at the mean age of 13.1 years and fertility rates were similar to their siblings (92). Even in the absence of exposure to API and despite the occurrence of menarche at a normal age, CCS were nevertheless shown to have a decreased reproductive capacity in comparison to healthy controls in another report (113). The risk of premature menopause was 8 and 0.8% (RR = 13.21, 95% CI = 3.26–53.51; p < 0.001) in CCS and siblings, respectively (108). The cumulative incidence of premature menopause was highest among CCS exposed to both alkylating agents and API (108). Evidence of ovarian insufficiency includes elevated gonadotropins, low anti-mullerian hormone (AMH) levels, and reduced mean ovarian volume (113). AMH is an acceptable marker of ovarian follicular reserve in female CCS, and low levels are indicative of declining ovarian function (116–119). Despite declining ovarian reserve in CCS, some survivors have successful pregnancies, with live birth rates of 63–73% (119–121).

Young CCS with ovarian failure may experience poor linear growth and poor bone mineralization. Older hypo-gonadal females can develop menopausal symptoms and are at risk for osteoporosis and cardiovascular disease (122, 123). Sex hormone replacement therapy is warranted in female CCS with ovarian failure. The use of cryopreserved ovarian tissue from pre-pubertal females carries the risk of re-seeding malignant cells and is considered experimental; by contrast, mature oocyte cryopreservation is no longer considered experimental and may represent a viable option for young pubertal females prior to gonadotoxic therapies (124). The availability of this technique, along with better ways of assessing ovarian reserve in females at risk of premature menopause may improve fertility prospects in the CCS population.

**BONE HEALTH RELATED COMPLICATIONS**

Childhood cancer survivors have an increased risk of poor bone health and decreased BMD (Table 2). Contributing factors include the primary cancer (increased osteoclast stimulation in hematological malignancies), treatment exposures, and concurrent hormone deficiencies (125). CCS treated with glucocorticoids and methotrexate or exposed to cranio-spinal radiotherapy, especially receiving >24 Gy of cranial irradiation are susceptible to decreased BMD (125, 126). The association between central nervous system exposures to radiotherapy and low BMD is likely due to radiation related endocrinopathies (deficiencies in GH and/or sex steroids in particular) (126). Lower BMD can be observed prior to cancer therapies because of the effect of the primary illness itself on bone (127). In a recent report on childhood ALL, the 3-year cumulative symptomatic fracture risk was 17.8% (n = 399). Fractures were more likely to occur during therapy than during follow up (127). The decline in BMD did not correlate with fracture risk in this study as well as in a report on survivors of osteosarcoma (127, 128). Recent studies have provided further reassurance regarding the continued recovery of BMD after the completion of therapy, a progress that continues, even in older individuals followed through adulthood (126, 129).

Optimizing bone health in CCS includes hormone replacement therapy for those with GHD, hypogonadism, and vitamin D deficiency. It is also recommended that survivors receive adequate nutritional calcium, participate in weight bearing activities, and avoid smoking (125, 128).

**OVERWEIGHT, OBESITY, AND DISORDERS OF GLUCOSE HOMEOSTASIS**

Obesity is a recognized public health challenge with far reaching consequences on overall states of health in the general population (130, 131) (Table 2). The prevalence of obesity and metabolic syndrome in the overall CCS population seems to be comparable to that observed in the general population (2, 130, 132). Hudson et al. demonstrated the prevalence of obesity, hypertension, dyslipidemia, and diabetes was 36.5, 22.6, 50.9, and 5.9%, respectively, in a cohort of CCS followed for 26.3 years after diagnosis (2). Nevertheless, survivors of ALL and brain tumors have significantly higher risks of obesity and overweight (133). Additional risk factors include female sex, doses of cranial radiotherapy >20 Gy, age at exposure <4-years old, and GHD (134, 135). CCS with a history of brain tumor development, radiotherapy, or surgery within the hypothalamus or near the sellar region are at risk of developing a particularly severe form of obesity characterized by hyperphagia and rapid weight gain, and which is sometimes referred to as “central” or “hypothalamic” obesity (136, 137). In these patients with significant hypothalamic injury, increased parasympathetic tone and ensuing hyperinsulinemia (the latter promoting fat storage) have been suggested as possible causes for this phenomenon (136, 137). Treatment approaches for this particular type of obesity have included octreotide and dextroamphetamine (137, 138). In a randomized, double-blind placebo-controlled study of 18 individuals with hypothalamic obesity, octreotide allowed the stabilization of BMI with lower rates of weight gain and lower insulin secretion over a treatment period of 6 months (137). The use of dextroamphetamine in five children with hypothalamic obesity allowed the
stabilization of BMI over a period of 24 months (138). The small numbers of patients enrolled in these studies with limited long-term follow-up data to support sustainable efficacy as well as the cost and possible side effects of the medications used in these reports have hindered the wider adoption of such treatment strategies. CCS were also shown to have a higher risk of diabetes mellitus, especially following exposure to TBI, abdominal radiotherapy, and alkylating agents (139, 140). Further research is needed in order to understand the mechanism by which such treatments leave lasting impacts on metabolism and glucose homeostasis as a preamble in optimizing the management of these disorders.

**SUMMARY**

Endocrine complications are common in CCS. Healthcare providers need to be aware of the lifelong endocrinopathies associated with treatment exposures. Further research is needed in order to improve risk prediction and develop patient centered screening strategies as the early diagnosis of endocrine disorders and timely treatment of these complications can improve overall states of health and the quality of life of individuals belonging to this vulnerable population.

**REFERENCES**

1. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin (2014) 64:83–103. doi:10.3322/caac.21219

2. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA (2013) 309:2371–81. doi:10.1001/jama.2013.6296

3. de Fine Licht S, Winther JF, Gudmundsdottir T, Holmqvist AS, Bonnesen TG, Asdahl PH, et al. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALICCS): a population-based cohort study. Lancet (2014) 383:1981–9. doi:10.1016/S0140-6736(13)62564-7

4. Brignardello P, Feliciotti F, Castiglione A, Chiabottai P, Corrias A, Fagioli F, et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics. Eur J Endocrinol (2013) 168:465–72. doi:10.1530/EJE-12-1043

5. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the stabilization of BMI over a period of 24 months (138). The small numbers of patients enrolled in these studies with limited long-term follow-up data to support sustainable efficacy as well as the cost and possible side effects of the medications used in these reports have hindered the wider adoption of such treatment strategies. CCS were also shown to have a higher risk of diabetes mellitus, especially following exposure to TBI, abdominal radiotherapy, and alkylating agents (139, 140). Further research is needed in order to understand the mechanism by which such treatments leave lasting impacts on metabolism and glucose homeostasis as a preamble in optimizing the management of these disorders.

**SUMMARY**

Endocrine complications are common in CCS. Healthcare providers need to be aware of the lifelong endocrinopathies associated with treatment exposures. Further research is needed in order to improve risk prediction and develop patient centered screening strategies as the early diagnosis of endocrine disorders and timely treatment of these complications can improve overall states of health and the quality of life of individuals belonging to this vulnerable population.

**REFERENCES**

1. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin (2014) 64:83–103. doi:10.3322/caac.21219

2. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA (2013) 309:2371–81. doi:10.1001/jama.2013.6296

3. de Fine Licht S, Winther JF, Gudmundsdottir T, Holmqvist AS, Bonnesen TG, Asdahl PH, et al. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALICCS): a population-based cohort study. Lancet (2014) 383:1981–9. doi:10.1016/S0140-6736(13)62564-7

4. Brignardello P, Feliciotti F, Castiglione A, Chiabottai P, Corrias A, Fagioli F, et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics. Eur J Endocrinol (2013) 168:465–72. doi:10.1530/EJE-12-1043

5. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the stabilization of BMI over a period of 24 months (138). The small numbers of patients enrolled in these studies with limited long-term follow-up data to support sustainable efficacy as well as the cost and possible side effects of the medications used in these reports have hindered the wider adoption of such treatment strategies. CCS were also shown to have a higher risk of diabetes mellitus, especially following exposure to TBI, abdominal radiotherapy, and alkylating agents (139, 140). Further research is needed in order to understand the mechanism by which such treatments leave lasting impacts on metabolism and glucose homeostasis as a preamble in optimizing the management of these disorders.
treated with GH: an analysis of GeNeSIS and HypoCCS. *Eur J Endocrinol.* (2013) 168:565–73. doi:10.1530/EJE-12-0967

32. Patterson BC, Chen Y, Sklar CA, Neglia J, Yousi Y, Mertens A, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab* (2014) 99:2030–7. doi:10.1210/jc.2013-4159

33. Follin C, Thilen U, Ahren B, Erfurth EM. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. *J Clin Endocrinol Metab* (2006) 91:1872–5. doi:10.1210/jc.2005-2298

34. Muir A. Precocious puberty. *Pediatr Rev* (2006) 27:373–81. doi:10.1542/pir.27-10-373

35. Partsch CJ, Sippell WG. Treatment of central precocious puberty. *Best Pract Res Clin Endocrinol Metab* (2002) 16:165–89. doi:10.1016/S0888-5451(02)00188-3

36. Armstrong GT, Whitten JA, Gajjar A, Kun LE, Chow EL, Stovall M, et al. Abnormal timing of menarche in survivors of central nervous system tumors: a report from the childhood cancer survivor study. *Cancer* (2009) 115:2562–70. doi:10.1002/cncr.24294

37. Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, et al. Age of onset of puberty following high-dose central nervous system radiation therapy. *Arch Pediatr Adolesc Med* (1996) 150:589–92. doi:10.1001/archpedi.1996.021703002300

38. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth in children treated with GH: an analysis of GeNeSIS and HypoCCS. *Eur J Endocrinol.* (1995) 133:1403–7. doi:10.1097/00043426-199512000-00013

39. Uruena M, Stanhope R, Chessells JM, Leiper AD. Impaired pubertal growth in GH-deficient childhood survivors of brain tumors receiving GH replacement. *J Pediatr*. (2004) 144(6):625–30. doi:10.1016/j.jpeds.2004.03.046

40. Lee PA. Central precocious puberty. An overview of diagnosis, treatment, and evolution. *Best Pract Res Clin Endocrinol Metab.* (2014) 27:10–37. doi:10.1016/j.beem.2013.12.003

41. Greulich WW, Pyle SI. *Radiographic Atlas of Skeletal Development of the Hand.* 2nd ed. Stanford, CA: Stanford University Press (1959).

42. Haber HP, Wollmann HA, Ranke MB. Pelvic ultrasonography: early differentiation between isolated premature thelarche and central precocious puberty. *Radiographic Atlas of Skeletal Development of the Hand.* 2nd ed. Stanford, CA: Stanford University Press (1959).

43. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, et al. Gonadal and sexual function in men treated for childhood cancer. *J Clin Endocrinol Metab.* (1999) 84:1472–9. doi:10.1210/jc.84.12.1472

44. Ureña M, Stanhope R, Chessells JM, Leiper AD. Impaired pubertal growth in GH-deficient childhood survivors of brain tumors receiving GH replacement. *J Pediatr*. (2004) 144(6):625–30. doi:10.1016/j.jpeds.2004.03.046

45. Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. *J Clin Endocrinol Metab.* (1999) 84:1472–9. doi:10.1210/jc.84.12.1472

46. Relander T, Cavallin-Stahl E, Garwicz S, Olsson AM, Willen M. Gonadal and sexual function in men treated for childhood cancer. *J Clin Endocrinol Metab.* (1999) 84:1472–9. doi:10.1210/jc.84.12.1472

47. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. *Neuroimmunomodulation* (2009) 16:272–83. doi:10.1159/0003216185

48. Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. *J Clin Endocrinol Metab.* (1999) 84:1472–9. doi:10.1210/jc.84.12.1472

49. Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillis A, et al. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. *Bone Marrow Transplant.* (1995) 15:71–6.

50. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Poulsen HS, Muller J. A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. *J Clin Endocrinol Metab.* (2003) 88:136–40. doi:10.1210/jc.2002-020380

51. Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. *J Clin Endocrinol Metab.* (2007) 92:4115–22. doi:10.1210/jc.2007-0297

52. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Rassbergs RF, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med.* (1995) 332:879–94. doi:10.1056/NEJM1995101433208203

53. Dazzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. *Growth Horm IGF Res.* (2006) 16(Suppl A):S30–40. doi:10.1016/j.ghir.2006.03.002

54. Ramelli GP, von der Weid N, Stanga Z, Mullis PE, Buerger U. Suprasellar germinomas in childhood and adolescence: diagnostic pitfalls. *J Pediatr Endocrinol Metab.* (1998) 11:693–7. doi:10.1515/PEM.1998.11.6.693

55. Silfen ME, Garvin JH Jr, Hays AP, Starkman HS, Aranoff GS, Levine IS, et al. Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism. *J Pediatr Hematol Oncol.* (2001) 23:150–3. doi:10.1097/00023436-200102000-00013

56. Spoudeas HA. Growth and endocrine function after chemotherapy and radiotherapy in childhood. *Eur J Cancer.* (2002) 38:1748–59. doi:10.1016/S0959-8049(02)00169-7

57. Di Iorigi N, Napoli F, Allegri AE, Olivieri I, Barletti E, Gallizia A, et al. Diabetes insipidus-diagnosis and management. *Horm Res Paediatr.* (2012) 77:69–84. doi:10.1159/000336333

58. Mishra G, Chandrasekhar SR. Management of diabetes insipidus in children. *Ind J Endocrinol Metab.* (2011) 15:1808–7. doi:10.4103/2230-8210.848858

59. Clement SC, van Eck-Smit BL, van Trosenburg AS, Kremer LC, Tytgat GA, van Santen HM. Long-term follow-up of the thyroid gland after treatment with 131I-Metabolodiodylguanidine in children with neuroblastoma: importance of continuous surveillance. *Pediatr Blood Cancer* (2013) 60:1833–8. doi:10.1002/pbc.24681

60. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. *Best Pract Res Clin Endocrinol Metab.* (2009) 23:793–800. doi:10.1016/j.beem.2009.08.003

61. Armstrong GT, Stovall M, Robinson LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. *Radiat Res.* (2010) 174:840–50. doi:10.1667/RR1903.1

62. Chow EL, Friedman DL, Stovall M, Yasui Y, Whitten JA, Robinson LL, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the childhood cancer survivor Study. *Pediatr Blood Cancer* (2009) 53:432–7. doi:10.1002/pbc.22082.
Barnes and Chemaitilly

Endocrinopathies in survivors of childhood neoplasia

72. Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. *J Clin Endocrinol Metab* (2014) 99:3189–91. doi:10.1210/je.2013-01590

73. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunblock treatment for patients with gastrointestinal stromal tumors. *Ann Intern Med* (2006) 145:660–4. doi:10.7326/0003-4819-145-9-20060110-00008

74. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. *J Clin Endocrinol Metab* (2006) 91:3361–6. doi:10.1210/jc.2005-0780

75. Ishiguro H, Y asuda Y, T omita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. *J Clin Endocrinol Metab* (2004) 89:5981–6. doi:10.1210/jc.2004-0838

76. Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF, et al. Thyroid dysfunction following hematopoietic cell transplantation in children: 30 years’ experience. *Blood* (2009) 113:306–8. doi:10.1182/blood-2008-08-173005

77. Jung YJ, Jeon YJ, Cho WK, Lee JW, Chung NG, Jung MH, et al. Risk factors for short term thyroid dysfunction after hematopoietic stem cell transplantation in children. *Eur J Pediatr* (2013) 172:298–303. doi:10.1007/s00431-013-2056-8

78. Sklar C, Boulad F, Small T, Kernan N. Endocrine complications of pediatric hematologic malignancies. *Bone Marrow Transplant* (2009) 33:577–81. doi:10.1038/sj.bmt.1706680

79. Rini BI, Talmaskar S, Shaeen F, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. *J Natl Cancer Inst* (2007) 99:81–3. doi:10.1093/jnci/djm008

80. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. *Thyroid* (2013) 23:1345–66. doi:10.1089/thy.2013.0241

81. Reulen RC, Froebisher C, Winter DL, Kelly J, Lanchance ER, Stiller CA, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. *JAMA* (2011) 305:2311–9. doi:10.1001/jama.2011.7747

82. Taylor AI, Croft AP, Palace AM, Winter DL, Reulen RC, Stiller CA, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British childhood cancer survivor study. *Int J Cancer* (2009) 125:2400–5. doi:10.1002/ijc.24581

83. Bhatti P, Vegaa LH, Ronckers CM, Sigurdsson AJ, Stovall M, Smith SA, et al. Risk of secondary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. *Radiat Res* (2010) 174:741–52. doi:10.1667/RR224.1

84. Mettler ML, Howard SC, Hudson MM, Chow AS, Krasin MJ, et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. *Pediatr Blood Cancer* (2006) 46:519–9. doi:10.1002/pbc.20541

85. Sklar C, Whitson J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the childhood cancer survivor study. *J Clin Endocrinol Metab* (2000) 85:3227–32. doi:10.1210/jc.2000-013237

86. Landier W, Bhatia S, Eschelman DA, Forte KJ, Sweeney T, Hester AL, et al. Development of risk-based guidelines for pediatric cancer survivors: the children's oncology group long-term follow-up guidelines from the children's oncology group late effects committee and nursing discipline. *J Clin Oncol* (2004) 22:4979–90. doi:10.1200/JCO.2004.11.032

87. Brignardello E, Corrias A, Isolato G, Palestini N, Cordero di Montezemolo L, Figali E, et al. Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. *J Clin Endocrinol Metab* (2008) 93:4840–3. doi:10.1210/jc.2008-1528
regimen without total-body irradiation – a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol (1997) 15:2238–46.

110. Rijkee SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA (1988) 259:2123–5. doi:10.1001/jama.1988.03700400003103

111. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol (1999) 33:2–8. doi:10.1002/(SICI)1096-911X(199907)33:1<2::AID-MPO2>3.0.CO;2-Z

112. Brydoy M, Fossa SD, Dahl O, Bjørør T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol (2007) 46:480–9. doi:10.1080/02841860601166958

113. El-Shalakany AH, Ali MS, Abdelmaksoud AA, Abd El-Ghany S, Hasam EA. Ovarian function in female survivors of childhood malignancies. Pediatr Hematol Oncol (2013) 30:328–35. doi:10.3109/08880018.2013.778927

114. Matsumoto M, Shinohara O, Ishiguro H, Shimizu T, Hattori K, Ichikawa M, et al. Ovarian function after bone marrow transplantation performed before menarche. Arch Dis Child (1999) 80:452–9. doi:10.1136/adc.80.5.452

115. Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 6:813–8.

116. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction (2006) 131:1–9. doi:10.1530/rep.1.00529

117. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP. Anti-Mullerian hormone production. Hum Reprod Update (2014) 20:570–85. doi:10.1093/humupd/dmu062

118. Nielsen SN, Andersen AN, Schmidt KT, Retnichter C, Schmiegelow K, Bentzen JG, et al. A 10-year follow-up of reproductive function in women treated for childhood cancer. Reprod Biomed Online (2013) 27:190–200. doi:10.1016/j.rbmo.2013.04.003

119. Green DM, Whitton JA, Stovall M, Mertens AC, Ruymann FB, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol (2002) 18:2239–47. doi:10.1001/1055-9665.EPI.09-0287

120. Asisenberg J, Hsieh K, Kalazitgouz G, Whitman E, Heller G, Schneider R, et al. Pregnancy outcomes among adult survivors of childhood cancer in the British childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev (2009) 18:2329–37. doi:10.1158/1055-9965.EPI-09-0287

121. Reulen RC, Zeegers MP, Wallace DM, Vater AK, Baart DE, et al. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction (2006) 131:1–9. doi:10.1530/rep.1.00529

122. Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, et al. Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation. J Clin Endocrinol Metab (2012) 97:3584–92. doi:10.1210/jc.2012-2393

123. Lustig RH, Post SR, Srinivansaboo K, Rose SR, Danish RK, Burghen GA, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab (2003) 88:611–6. doi:10.1210/jc.2002-021180

124. Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniofacial hypoplasia. Arch Pediatr Adolesc Med (2002) 156:887–92. doi:10.1001/archpedi.156.9.8887

125. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab (2003) 88:5586–92. doi:10.1210/jc.2002-030003

126. Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniofacial hypoplasia. Arch Pediatr Adolesc Med (2002) 156:887–92. doi:10.1001/archpedi.156.9.8887

127. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab (2003) 88:5586–92. doi:10.1210/jc.2002-030003

Conflict of Interest Statement: Dr. Wassim Chemaitilly has accepted speaker fees from Novo Nordisk and JCR Pharmaceuticals (Japan). Dr. Nicole Barnes has no conflicts of interest to disclose.